Evidence map›Paper›PMID 39592656›Full record

ArticleScientific reports2024

miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.

Mateusz Bilski, Marzanna Ciesielka, Magdalena Orzechowska, Bożena Jarosz, Paulina Całka, Sylwia Bilska, Agata Banach, Gabriela Czaja, Jacek Fijuth, Łukasz Kuncman

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mateusz BilskiDepartment of Radiotherapy, Medical University of Lublin, Lublin, Poland.
Marzanna CiesielkaChair and Department of Forensic Medicine, Medical University of Lublin, Lublin, Poland.
Magdalena OrzechowskaDepartment of Molecular Carcinogenesis, Medical University of Łódź, Łódź, Poland.
Bożena JaroszChair and Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, Lublin, Poland.
Paulina CałkaChair and Department of Forensic Medicine, Medical University of Lublin, Lublin, Poland.
Sylwia BilskaClinical Genetics Center, St. John's Cancer Center, Lublin, Poland.
Agata BanachChair and Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, Lublin, Poland.
Gabriela CzajaChair and Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, Lublin, Poland.
Jacek FijuthDepartment of Radiotherapy, Medical University of Łódź, Łódź, Poland.
Łukasz KuncmanDepartment of Radiotherapy, Medical University of Łódź, Łódź, Poland. lukasz.kuncman@umed.lodz.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are the predominant cause of cancer-related deaths among the young population. Even after incorporation of IDH1/2 mutations and 1p19q codeletion there are doubts regarding adjuvant treatment in WHO G2/G3 gliomas. miRNA molecules control about 30% of all genes, also many oncogenes, tumor suppressor genes and genes responsible for the response to ionizing radiation and systemic treatment. Patients with brain gliomas exhibit miRNA disorders. We aimed to evaluate the expression of miR-200 family members in relation to selected clinico-pathological factors and their prognostic value. We enrolled 53 patients diagnosed with WHO G2/G3 brain gliomas treated between 2012-2016. RT-qPCR based expression of miR-200 family was assessed in tumor and surrounding non-cancerous tissue. An analysis of selected clinico-pathological features was carried out. A logistic regression model was prepared for the miRNA signature. The predictive potential of the signature was assessed using the ROC curve. A stepwise backward regression model was used to select variables with a significant predictive potential related to OS. It was shown that miR-200a-3p, miR-200a-5p, miR-200c-5p, miR-141-3p and miR-429 can be independent predictors of survival. Better 2- and 5-year OS was associated with higher expression of miR-200a-3p, miR141-3p and lower expression of miR-200a-5p, miR-200c-5p, miR-429. The strongest predictors of survival were miR-200a-5p, miR-200b-3p, miR-200c-5p, miR-141-3p, miR-429, tumor volume and CTV. Members of the miR-200 family exhibit prognostic value for 2- and 5-year OS. Presented predictive models of survival may be clinically useful for treatment optimization.

Indexed as

Brain NeoplasmsGliomaMicroRNAsAdultAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm GradingPrognosisYoung AdultBiomarkers, TumorMicroRNAsMIRN200 microRNA, humanBrain tumorGliomaMiRNAPrognostic factorSurvival

Identifiers

PMID39592656
PMCPMC11599569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.